COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration
COEPTIS (NASDAQ: COEP) has successfully completed its Series A Preferred financing round, raising an additional $5.7 million for a total of $10 million. The latest funding was led by CJC Investment Trust, controlled by board member Christopher Calise. The Series A Preferred is convertible to common stock at $8.00 per share, with investors receiving a 15% equity stake in two newly formed subsidiaries: SNAP Biosciences and GEAR Therapeutics.
The financing follows an initial closure of $4.3 million in June 2024. Funds will be used to strengthen the company's balance sheet, repay obligations, and support general corporate purposes. Notably, the capital will accelerate COEPTIS' integration of AI solutions and automation capabilities, particularly through their recently acquired NexGenAI Affiliates Network platform, aimed at enhancing research processes and operational efficiency in the biopharmaceutical sector.
COEPTIS (NASDAQ: COEP) ha completato con successo il suo round di finanziamento di Serie A Preferita, raccogliendo ulteriori 5,7 milioni di dollari per un totale di 10 milioni di dollari. Il finanziamento più recente è stato guidato dal CJC Investment Trust, controllato dal membro del consiglio Christopher Calise. La Serie A Preferita è convertibile in azioni ordinarie a 8,00 dollari per azione, con gli investitori che ricevono una partecipazione azionaria del 15% in due nuove sussidiarie: SNAP Biosciences e GEAR Therapeutics.
Il finanziamento segue una chiusura iniziale di 4,3 milioni di dollari avvenuta a giugno 2024. I fondi saranno utilizzati per rafforzare il bilancio dell'azienda, ripagare obbligazioni e supportare le esigenze aziendali generali. È importante notare che il capitale accelererà l'integrazione da parte di COEPTIS di soluzioni AI e capacità di automazione, in particolare attraverso la loro recentemente acquisita piattaforma NexGenAI Affiliates Network, mirata a migliorare i processi di ricerca e l'efficienza operativa nel settore biofarmaceutico.
COEPTIS (NASDAQ: COEP) ha completado con éxito su ronda de financiamiento preferente Serie A, recaudando un adicional de 5.7 millones de dólares para un total de 10 millones de dólares. La última financiación fue liderada por CJC Investment Trust, controlado por el miembro de la junta Christopher Calise. La Serie A Preferente es convertible a acciones comunes a 8.00 dólares por acción, con los inversores recibiendo una participación del 15% en dos nuevas subsidiarias: SNAP Biosciences y GEAR Therapeutics.
El financiamiento sigue un cierre inicial de 4.3 millones de dólares en junio de 2024. Los fondos se utilizarán para fortalecer el balance de la empresa, pagar obligaciones y apoyar propósitos corporativos generales. Cabe destacar que el capital acelerará la integración de soluciones de IA y capacidades de automatización por parte de COEPTIS, especialmente a través de su recientemente adquirida plataforma NexGenAI Affiliates Network, destinada a mejorar los procesos de investigación y la eficiencia operativa en el sector biofarmacéutico.
COEPTIS (NASDAQ: COEP)가 시리즈 A 우선주 자금 조달을 성공적으로 완료하고 추가로 570만 달러를 모금하여 총 1000만 달러를 모았습니다. 최근 자금 조달은 이사회 멤버인 크리스토퍼 칼리세가 통제하는 CJC Investment Trust가 주도했습니다. 시리즈 A 우선주는 주당 8.00달러에 보통주로 전환 가능하며, 투자자들은 SNAP Biosciences와 GEAR Therapeutics의 두 개 신설 자회사의 15% 지분을 받게 됩니다.
이번 자금 조달은 2024년 6월에 430만 달러로 초기 마감을 한 후 이루어졌습니다. 자금은 회사의 재무상태를 강화하고 의무를 갚으며 일반 기업 목적을 지원하는 데 사용됩니다. 특히 이번 자본은 COEPTIS가 AI 솔루션과 자동화 기능을 통합하는 데 가속도를 붙일 것이며, 이는 최근 인수한 NexGenAI Affiliates Network 플랫폼을 통해 연구 프로세스와 생명공학 분야의 운영 효율성을 향상시키는 것을 목표로 합니다.
COEPTIS (NASDAQ: COEP) a réussi à conclure son tour de financement préférentiel de série A, levant un montant supplémentaire de 5,7 millions de dollars pour un total de 10 millions de dollars. Le dernier financement a été dirigé par le CJC Investment Trust, contrôlé par le membre du conseil Christopher Calise. La série A préférentielle est convertible en actions ordinaires à 8,00 dollars par action, les investisseurs recevant une participation de 15 % dans deux nouvelles filiales : SNAP Biosciences et GEAR Therapeutics.
Ce financement fait suite à une première clôture de 4,3 millions de dollars en juin 2024. Les fonds seront utilisés pour renforcer le bilan de l'entreprise, rembourser des obligations et soutenir des objectifs d'entreprise généraux. Il est à noter que le capital accéléra l'intégration par COEPTIS des solutions d'IA et des capacités d'automatisation, notamment grâce à leur plateforme récemment acquise NexGenAI Affiliates Network, visant à améliorer les processus de recherche et l'efficacité opérationnelle dans le secteur biopharmaceutique.
COEPTIS (NASDAQ: COEP) hat erfolgreich seine Finanzierungsrunde der Serie A Bevorzugt abgeschlossen und zusätzlich 5,7 Millionen Dollar gesammelt, was insgesamt 10 Millionen Dollar ergibt. Die letzte Finanzierung wurde von CJC Investment Trust geleitet, das von dem Vorstandsmitglied Christopher Calise kontrolliert wird. Die Serie A Bevorzugt ist zu Stammaktien zum Preis von 8,00 Dollar pro Aktie umwandelbar, wobei die Investoren eine 15%ige Beteiligung an zwei neu gegründeten Tochtergesellschaften erhalten: SNAP Biosciences und GEAR Therapeutics.
Die Finanzierung folgt einem ersten Abschluss von 4,3 Millionen Dollar im Juni 2024. Die Mittel werden verwendet, um die Bilanz des Unternehmens zu stärken, Verpflichtungen zu begleichen und allgemeine Unternehmensziele zu unterstützen. Bemerkenswert ist, dass das Kapital die Integration von KI-Lösungen und Automatisierungsfähigkeiten durch COEPTIS beschleunigen wird, insbesondere durch ihre kürzlich erworbene NexGenAI Affiliates Network-Plattform, die darauf abzielt, Forschungsprozesse und die operative Effizienz im biopharmazeutischen Sektor zu verbessern.
- Secured additional $5.7M financing, completing $10M Series A round
- 15% equity interest granted in two new subsidiaries
- Strategic expansion into AI and technology integration
- Conversion price set at $8.00 per share for Series A Preferred
- Dilution risk for existing shareholders through convertible preferred shares
- Outstanding obligations requiring repayment from raised funds
Insights
The successful completion of COEPTIS's
The participation of board member Christopher Calise's CJC Investment Trust as lead investor sends a powerful signal of insider confidence. This internal backing, combined with the premium conversion price relative to the current market cap of
The debt reduction component is particularly significant given the current high-interest-rate environment. By strengthening the balance sheet and eliminating outstanding obligations, COEPTIS is positioning itself for improved financial flexibility and reduced carrying costs. The allocation towards AI integration, particularly through the NexGenAI platform, aligns with industry trends toward operational automation and efficiency optimization in the biotech sector.
The subsidiary equity component is an innovative financing feature that provides investors direct exposure to specialized business units, potentially unlocking additional value through future spinoffs or strategic transactions. This structure creates embedded optionality while maintaining operational synergies within the broader corporate framework.
COEPTIS's strategic emphasis on AI integration through the NexGenAI platform represents a sophisticated approach to addressing key operational challenges in the highly regulated biopharmaceutical sector. The focus on marketing and operational efficiencies through AI tools is particularly noteworthy, as it targets two critical cost centers in biotech development.
The implementation of AI-driven tools in regulatory compliance and marketing optimization could provide significant competitive advantages. By automating complex compliance processes and enhancing marketing efficiency, COEPTIS is positioning itself to reduce operational overhead while potentially accelerating time-to-market for new therapeutics.
The creation of dedicated subsidiaries (SNAP Biosciences and GEAR Therapeutics) suggests a structured approach to technology integration, potentially allowing for more focused development of AI applications in specific therapeutic areas. This organizational structure could facilitate faster innovation cycles while maintaining regulatory compliance through specialized oversight.
The financing was led by CJC Investment Trust, an entity controlled by board member Christopher Calise, through an increase in their initial investment in the round. Under the terms of the latest financing, the Series A Preferred is convertible into shares of the Company's common stock at a price of
"We're thrilled to announce the successful closure of our second Series A Preferred financing," said Brian Cogley, CFO of COEPTIS. "This funding is pivotal as we expand our operational capabilities and enhance shareholder value through our new Technology Division. The integration of AI-driven tools, particularly from our recent acquisition of the NexGenAI Affiliates Network platform, is vital in revolutionizing our approach to marketing and operational efficiencies in the highly regulated biopharmaceutical sector."
The proceeds from this financing will be utilized to strengthen the Company's balance sheet, repay outstanding obligations, and support general corporate purposes, alongside the
"This additional financing enables Coeptis to not just fortify its mission in cell therapy but also empowers us to drive innovation in technology and AI," added Dave Mehalick, President and CEO of COEPTIS. "By fostering a culture of responsible innovation, we aim to capitalize on diverse growth opportunities, creating a self-sustaining business model that establishes a strong foundation for long-term success and profitability."
About COEPTIS, Inc.
COEPTIS, Inc., together with its subsidiaries Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., and SNAP Biosciences, Inc. (collectively "Coeptis"), is a biopharmaceutical and technology company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.
The Company's therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. COEPTIS is also developing a universal, multi-antigen CAR technology licensed from the University of
Building on its core competencies, COEPTIS has recently established a Technology Division, which focuses on enhancing operational capabilities through advanced technologies. This division features AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group, designed to optimize business processes and improve overall efficiency.
Headquartered in
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the inability to recognize the anticipated benefits of the Deverra licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (3) the risks that the Company's products in development or the newly-licensed assets fail clinical trials or are not approved by the
Contacts
IR@coeptistx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/coeptis-completes-10-million-series-a-preferred-financing-round-reinforcing-commitment-to-technological-innovation-and-ai-integration-302369957.html
SOURCE Coeptis Pharmaceuticals, Inc.
FAQ
How much did COEPTIS (COEP) raise in their latest Series A Preferred financing round?
What is the conversion price for COEPTIS (COEP) Series A Preferred shares?
What equity stake did Series A investors receive in COEPTIS (COEP) subsidiaries?
How will COEPTIS (COEP) use the Series A financing proceeds?
Who led the latest Series A Preferred financing round for COEPTIS (COEP)?
